Hightide Therapeutics Inc (HK:2511)
:2511
Top Page
Hightide Therapeutics Inc
(2511)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$2.50
▼(-18.03% Downside)
Action:UpgradedDate:12/30/25
The score is primarily held back by weak financial performance (no revenue, ongoing cash burn, and increased debt despite improved losses). Technical indicators are mixed with neutral momentum and negative MACD, while valuation remains constrained by losses and the absence of a dividend yield.
Positive Factors
Clinical Trial Success
The success of HTD1801 in Phase III trials positions it as a potential foundational therapy, enhancing the company's product pipeline and market potential.
Negative Factors
Cash Burn
Persistent negative cash flow indicates reliance on external funding, increasing financial risk and potential dilution for shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Trial Success
The success of HTD1801 in Phase III trials positions it as a potential foundational therapy, enhancing the company's product pipeline and market potential.
Read all positive factors
Hightide Therapeutics Inc (2511) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.66B
Dividend YieldN/A
Average Volume (3M)1.41M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth47.42%
CountryHK
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Hightide Therapeutics Inc Business Overview & Revenue Model
Company Description
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its ...
How the Company Makes Money
Hightide Therapeutics Inc generates revenue through the development and commercialization of its proprietary drug candidates. The company earns money by advancing its product pipeline through clinical trials and securing regulatory approvals for i...
Hightide Therapeutics Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -2.02M | -1.30M | -1.56M |
| EBITDA | -196.37K | -444.22K | -1.04B | -229.56M | -131.80M |
| Net Income | -291.16K | -381.79K | -1.04B | -190.24M | -221.15M |
Balance Sheet | |||||
| Total Assets | 528.48M | 559.93M | 795.04M | 855.82M | 777.23M |
| Cash, Cash Equivalents and Short-Term Investments | 467.01M | 490.52M | 735.70M | 828.33M | 763.91M |
| Total Debt | 99.47M | 77.91M | 16.43M | 1.27B | 1.01B |
| Total Liabilities | 160.66M | 135.76M | 92.26M | 1.33B | 1.05B |
| Stockholders Equity | 315.51M | 424.17M | 702.77M | -470.53M | -271.77M |
Cash Flow | |||||
| Free Cash Flow | -112.44M | -299.46M | -368.56M | -172.90M | -90.12M |
| Operating Cash Flow | -107.85M | -294.81M | -367.67M | -172.71M | -88.40M |
| Investing Cash Flow | 65.21M | -89.72M | 321.64M | -415.66M | 1.59M |
| Financing Cash Flow | 60.92M | 54.79M | 399.46M | 46.03M | 493.98M |
Hightide Therapeutics Inc Technical Analysis
Positive
3.05
Price Trends
2.77
Positive
2.81
Positive
3.15
Positive
Market Momentum
0.11
Positive
60.42
Neutral
53.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2511, the sentiment is Positive. The current price of 3.05 is below the 20-day moving average (MA) of 3.05, above the 50-day MA of 2.77, and below the 200-day MA of 3.15, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 60.42 is Neutral, neither overbought nor oversold. The STOCH value of 53.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2511.
Hightide Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$5.60B | -5.30 | 2.04% | ― | 1447.56% | ― | |
46 Neutral | HK$1.66B | -5.33 | -39.41% | ― | ― | 47.42% | |
45 Neutral | HK$2.06B | 33.28 | 43.89% | ― | 178.36% | 86.74% | |
43 Neutral | HK$1.02B | -4.22 | -14.48% | ― | ― | -41.48% | |
41 Neutral | HK$912.08M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:2511
Hightide Therapeutics Inc
3.26
1.96
150.77%
HK:2137
Brii Biosciences Limited
1.42
-0.23
-13.94%
HK:6998
Genor Biopharma Holdings Limited
2.79
0.97
53.30%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.40
212.50%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.80
57.55%
HK:2181
Mabpharm Limited
0.50
0.00
0.00%
Hightide Therapeutics Inc Corporate Events
HighTide Therapeutics Names Veteran Cardiometabolic Leader Filip Surmont as Chief Medical Officer
Feb 2, 2026
HighTide Therapeutics has appointed veteran pharmaceutical executive and clinician Dr. Filip Surmont as Chief Medical Officer, tasking him with leading global medical strategy, clinical development and medical affairs to accelerate the progress an...
HighTide Therapeutics Sets Up Nomination Committee to Bolster Governance
Dec 24, 2025
HighTide Therapeutics, Inc. has formally established a Nomination Committee of its board of directors, effective from the date its shares were listed on the Hong Kong Stock Exchange, to oversee the nomination and governance process for directors a...
HighTide Therapeutics’ HTD1801 Outperforms in Phase III Trial
Dec 2, 2025
HighTide Therapeutics announced positive results from its Phase III HARMONY trial, where its drug HTD1801 showed superior improvements in cardiometabolic markers for patients with type 2 diabetes mellitus compared to dapagliflozin. The trial’...
HighTide Therapeutics Showcases Renal Benefits of HTD1801 at ASN Meeting
Nov 7, 2025
HighTide Therapeutics presented evidence at the ASN Annual Meeting showing that their drug HTD1801 benefits patients with mild renal impairment by improving eGFR trajectory and normalizing renal function. This development highlights HTD1801’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.